NCT00553098 - Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

March 31, 2015

Conditions

Immunodeficiency SyndromeNon-Cancer Diagnosis

Interventions

BIOLOGICAL

Alemtuzumab

Given IV

PROCEDURE

Allogeneic Bone Marrow Transplantation

Undergo HCT

PROCEDURE

Allogeneic Hematopoietic Stem Cell Transplantation

Undergo HCT

DRUG

Cyclosporine

Given PO or IV

DRUG

Fludarabine Phosphate

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative study

DRUG

Mycophenolate Mofetil

Given PO or IV

RADIATION

Total-Body Irradiation

Undergo low dose TBI

Trial Locations (6)

37232

Vanderbilt University/Ingram Cancer Center, Nashville

44195

Cleveland Clinic Foundation, Cleveland

53201

Children's Hospital of Wisconsin, Milwaukee

97239

Oregon Health and Science University, Portland

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

94609-1809

Children's Hospital and Research Center at Oakland, Oakland

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER